Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

rcent, respectively. Responders in both the FLT3 ITD-positive and FLT3 ITD-negative groups had at least a doubling of median overall survival compared to non-responders (26 vs. nine weeks for FLT3 ITD-positive, and 19 vs. nine weeks for FLT3 ITD-negative. The most common drug-related AEs in the study were gastrointestinal-related (nausea, vomiting, dysgeusia, abdominal pain, anorexia, diarrhea), skin irritation, and peripheral edema. All of these drug-related adverse events occurred in less than 15% of the study population, with most occurring in less than 10% of patients, and were primarily mild to moderate in severity. In addition, some patients experienced QTcF interval prolongation, which was asymptomatic and reversible. The maximum tolerated dose was determined to be 200 mg continuous once-daily dosing.

For more information about the ACE Study, please visit http://www.clinicaltrials.gov/ct2/show/NCT00989261?term=ac220&rank=1, or call 858-334-2136 in the United States, or email to ACEstudy@ambitbio.com.

About AC220

AC220, Ambit's lead product candidate, is a novel, potent, highly selective, orally bioavailable second-generation FLT3 inhibitor currently under evaluation as a monotherapy treatment in adult and elderly patients with relapsed or refractory acute myeloid leukemia (AML). AML is the most common type of blood cancer in adults, and the kinase FLT3 is mutated and constitutively activated in 25-40 percent of such patients. FLT3 ITD mutations predict poor prognosis and decreased response to existing treatments, including chemotherapy and hematopoietic stem cell transplant. Ambit leveraged KINOMEscan(TM), the company's proprietary, high-throughput method for screening small molecule compounds against a large number of human kinases, to advanc
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015 According to a new ... Trends & Forecasts (2015-2020), , published by Mordor Intelligence, the ... by the end of 2020, with North America ... than 40% of the global market size. The Global market ... of 13.7% during the period of (2015-2020).      ...
(Date:7/29/2015)... July 29, 2015  HealthSouth Corporation (NYSE: ... providers of post-acute healthcare services, offering both facility-based ... of operations for the second quarter ended June 30, ... characterized by strong volume growth in both segments ... said Jay Grinney, President and Chief Executive Officer ...
(Date:7/29/2015)... ... 29, 2015 , ... Brady (NYSE:BRC), a global leader in ... To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard and ... example of an accurate label, and pictogram uses and meanings. , “With changes ...
(Date:7/29/2015)... 29, 2015  Indivior PLC (LON: INDV) today announced ... spray was accepted and received Priority Review by the ... of opioid overdose. This naloxone nasal spray comes as ... optimal absorption into the nasal mucosa. 1 The ... individuals may be better equipped to help an opioid ...
Breaking Biology Technology:Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31HealthSouth Reports Results for Second Quarter 2015 32HealthSouth Reports Results for Second Quarter 2015 33HealthSouth Reports Results for Second Quarter 2015 34
... biologically safer water through point-of-use ... ultrafiltration, ... ),a medical device company, announced today that it will be exhibiting ... Conference and Technical Exhibition in National Harbor,Maryland, July 20th-23rd, 2008. Building ...
... Revenues While Advancing Three Major Clinical Programs, and Securing ... ... Million -, TUSTIN, Calif., July 14 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... ended April 30, 2008. Total revenues for FY 2008,increased 64% to ...
... Raptor,Pharmaceuticals Corp. (OTC Bulletin Board: RPTP), today ... to the Company,s board of,directors and Stephen C. ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO ), Christopher M. ... stated, "I would like to welcome Drs. Franklin ...
Cached Biology Technology:Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 2Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 3Nephros Exhibiting at Maryland Ashe Conference July 20th-23rd 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 10Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008 11Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 2Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 3Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 4Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board 5
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... A major asthma discovery by a researcher at the ... licensed by MedImmune, a leading innovation-focused biotechnology company and ... the discovery to explore its use in the development ... Under the agreement, MedImmune was granted ...
... The availability of healthy food choices and your quality ... to two studies conducted by researchers at the Johns ... food availability and diet quality among Baltimore City and ... healthy foods was associated with quality of diet and ...
... Cutting edge science has finally put to rest a ... long-romanticized story of a child,s escape from the firing ... Medical School in cooperation with Institutions of ... Sciences (MHRC) have confirmed that human remains found ...
Cached Biology News:La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 2La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery 3Healthy food availability could depend on where you live -- so does the quality of your diet 2Healthy food availability could depend on where you live -- so does the quality of your diet 3UMMS researchers publish DNA identification of czar's children 2UMMS researchers publish DNA identification of czar's children 3UMMS researchers publish DNA identification of czar's children 4
Request Info...
...
...
... cytostatic and anti-viral agent. Inhibits several important steps ... formation of HUVEC cells. Also reduces intracellular reactive ... IL-8 release of endothelial cells. ... 16 O 8 MolWeight: ...
Biology Products: